Pharmacodynamics of LY2963016 Compared to LANTUS in Subjects With Type 1 Diabetes Mellitus

Trial Profile

Pharmacodynamics of LY2963016 Compared to LANTUS in Subjects With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Sep 2014 Primary endpoint (Pharmacodynamics: Duration of Action of LY2963016 and Lantus) has been met.
    • 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 31 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top